Yale Engage Cancer Series: Defining Mechanisms and Biomarkers of Sensitivity & Resistance To Anti-Cancer Treatments

In conjunction with Yale Cancer Center, we present Yale Engage, an interactive webinar series promoting impactful collaboration between academic experts and industry executives. This is designed for a broad corporate audience, but particularly of interest for executives and leaders in Research & Development, Business Development, Strategy, and Innovation in sectors such as Biotechnology, Pharmaceutical, Healthcare, Technology, and Venture Capital.

These sessions will feature corporate speakers with a panel of renowned Yale physicians and scientists addressing critical challenges.

With real-time dialogue and strategic introductions, we will pinpoint issues and research goals to advance shared, scalable solutions.  In the fight against cancer, Yale Cancer Center is at the forefront of understanding the fundamental mechanisms of cancer biology and in developing effective cancer treatment therapies.  The Cancer Center harnesses the resources of the Yale School of Medicine and Smilow Cancer Hospital at Yale New Haven to advance cancer research, prevention, and patient care, as well as community outreach and education.

The discussion will highlight the ability to create and leverage interdisciplinary teams to advance science in drug discovery and development and delivery systems.  We will touch upon the infrastructure and capabilities of the Yale Center for Molecular Discovery and our proven ability to advance innovative concepts to industry ready translation.

Defining Mechanisms and Biomarkers of Sensitivity & Resistance To Anti-Cancer Treatments

The discussion will highlight mechanisms of resistance to clinical applications, developing and applying biomarkers, and drug sensitivity, as well as addressing major challenges, such as:

• Identifying new targets for specific tumors
• Dissecting the complexity of drug resistance
• Reviewing systemic influences on tumors
• Pinpointing next gen biomarkers

Moderator: Barbara Burtness, MD, Professor of Medicine (Medical Oncology), Yale School of Medicine; Disease Aligned Research Team Leader, Head and Neck Cancers Program; Co-Leader, Developmental Therapeutics, Yale Cancer Center
Panelists from the Yale School of Medicine:

• Megan King, PhD
• Mark Lemmon, PhD
• Katerina Politi, PhD
• Kurt Schalper, MD, PhD
• Qin Yan, PhD